 EAST SETAUKET, NY, June 02, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc. Nasdaq: LIXT, a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixtes first-in-class protein phosphatase 2A PP2A inhibitor LB-100 with a standard regimen for previously untreated, extensive stage-disease small cell lung cancer ED-SCLC NCT04560972. 